HAVCR2 and non-small cell lung carcinoma: To assess the prognostic value of circulating anti-TERT Th1 immunity and exhausted PD-1+/TIM-3+ T cells in this cohort of treatment-naive NSCLC, we considered two groups of patients with low versus high circulating rates of these two immune parameters (see details in the Methods section and Supplementary Table 3).